Table 1.
Baseline characteristics
| Characteristic | Patients (n = 79) |
|---|---|
| Male (n, %) | 59 (74.9%) |
| Age, years (median, IQR) | 54.0 (43.8–64.3) |
|
Genetic arrhythmia (n, %)
DPP6 mutation LQTS HCM (familial) iVF |
6 (7.6%)
1 (14.3%) 1 (14.3%) 2 (28.6%) 2 (28.6%) |
| Ischaemic CMP (n, %) | 29 (36.7%) |
|
Non-ischaemic CMP (n, %)
Dilated CMP Non-compaction CMP CMP eci Myocarditis Peri-partum CMP |
41 (51.9%)
28 (68.3%) 2 (4.8%) 2 (4.9%) 7 (17.1%) 2 (4.9%) |
| Wolff-Parkinson-White syndrome (n, %) Other (n, %) |
1 (1.3%) 2 (2.5%) |
|
Previous CIED implant (n, %)
One chamber TV-ICD Dual chamber TV-ICD S-ICD Pacemaker CRT-D |
26 (32.9%)
2 (7.7%) 6 (23.1%) 6 (23.1%) 1 (3.8%) 11 (42.3%) |
|
Complication previous implant (n, %)
Infection |
23 (88.5%)
23 (100%) |
|
Indication WCD (n, %)
Newly diagnosed iCMP Newly diagnosed non-iCMP Bridging to implant due to infection Bridging to implant due to other reason |
–
12 (15.2%) 34 (43.0%) 23 (29.1%) 10 (11.9%) |
|
Ventricular arrhythmias (n, %)
Ventricular tachycardia Ventricular fibrillation Non-sustained ventricular tachycardia |
58 (73.4%)
16 (27.6%) 10 (17.2%) 32 (55.2%) |
|
Supraventricular tachycardia (n, %)
Atrial fibrillation Atrial flutter Atrial tachycardia AV(N)RT |
16 (20.8%)
13 (81.3%) 1 (6.3%) 1 (6.3%) 1 (6.3%) |
| LVEF, % (median, IRQ) | 25.0 (18.0–39.3) |
AV(N)RT atrioventricular (nodal) re-entry tachycardia, CIED cardio implantable electronic device, CMP cardiomyopathy, iCMP ischaemic CMP, non-iCMP non-ischaemic CMP, DPP6 dipeptidylpeptidase 6, HCM hypertrophic cardiomyopathy, IQR interquartile range, LQTS long-QT syndrome, LVEF left ventricular ejection fraction, S-ICD subcutaneous implantable cardioverter-defibrillator, TV-ICD transvenous implantable cardioverter-defibrillator, WCD wearable cardioverter-defibrillator